Author

Nicolas Williet 1

1 CHU, Dr., Saint Priest en Jarez, France

AZATHIOPRINE DOSE REDUCTION  INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A PROSPECTIVE STUDY

Emilie Del Tedesco, Stéphane Paul, hubert marotte, Nicolas Williet, Jean Marc Phelip, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Xavier Roblin

CYTOMEGALOVIRUS INFECTION IS ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH ULCERATIVE COLITIS TREATED BY VEDOLIZUMAB

Xavier Roblin, Léa BRICHET, Sylvie Pillet, Emilie Del Tedesco, Jean Marc Phelip, Bruno Pozzetto, Nicolas Williet

DEVELOPMENT OF A NEW SCORE PREDICTIVE OF SUSTAINED CLINICAL REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER INFLIXIMAB-AZATHIOPRINE COMBOTHERAPY.

Baptiste Sivard, Nicolas Williet, Jean-Marc Phelip, Emilie Del Tedesco, Stéphane Paul, Xavier Roblin

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

Quentin Tournier, Stéphane Paul, Nicolas Williet, Anne Emmanuelle Berger, Pauline Veyrard, Gilles Boschetti, J. Marc Phelip, Bernard Flourie, Stéphane Nancey, Xavier Roblin

IBD-INFO QUESTIONNAIRE: A MULTICENTER FRENCH UP-TO-DATE SURVEY OF PATIENT KNOWLEDGE IN INFLAMMATORY BOWEL DISEASE

Pauline Danion, Anthony Buisson, Xavier Roblin, Nicolas Mathieu, Anne-Laure Charlois, Nicolas Williet, Emilie Del Tedesco, Bernard Flourie, Stéphane Nancey, Gilles Boschetti

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Capucine Genin, Nicolas Williet, Anne Emmanuelle Berger, Pauline Veyrard, Jean Marc Phelip, Gilles Boschetti, Stéphane Nancey, Stéphane Paul, Xavier Roblin

INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL

Xavier Roblin, Stéphane Paul, Gilles Boschetti, Jean Marc Phelip, Emilie Del Tedesco, Stéphane Nancey, Nicolas Williet, Bernard Flourie

PATIENT REPORTED-OUTCOMES IN A NATIONWIDE SURVEY AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: THE BURDEN OF INFLAMMATORY BOWEL DISEASE (B.I.R.D) STUDY

Nicolas Williet, Corinne Gower-Rousseau, Charlotte Andrianjafy, Alain Olympie, Anne Buisson, Laurent Beaugerie, Laurent Peyrin-Biroulet

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

Pauline Veyrard, Ren Mao, Nicolas Williet, Stéphane Nancey, Gilles Boschetti, Bernard Flourie, Jean Marc Phelip, Xavier Roblin, Stéphane Paul

SOLUBLE MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 AND RETINOIC ACID ARE POTENTIAL TOOLS FOR THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A PROOF OF CONCEPT STUDY

Stéphane Paul, Stéphane Nancey, Nicolas Williet, Jerome Filippi, Anne-Emmanuelle Berger, Bernard Flourie, Xavier Roblin

Item 1 - 10 / 11
1
2